Your institution may have rights to this item. Sign in to continue.
Title
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.